Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHBY)

Delayed Data
As of Nov 22
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx
9:20am / Zacks.com - Paid Partner Content
Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss
Nov 20 / Zacks.com - Paid Partner Content
Parkinson's Space in Focus as Acorda Stops Tozadenant Trial
Nov 22 / Zacks.com - Paid Partner Content
Roche Stock Surges on Trial Successes in Cancer, Haemophilia
Nov 20 / TheStreet.com - Paid Partner Content
Global In Vitro Diagnostic Market Booms: Stocks in Focus
Nov 22 / Zacks.com - Paid Partner Content
Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion
Nov 17 / Zacks.com - Paid Partner Content
Company News For Nov 21, 2017
Nov 21 / Zacks.com - Paid Partner Content
Cancer Space Update: Label Expansion for Three Major Drugs
Nov 17 / Zacks.com - Paid Partner Content
Roche Reports Positive Data From Tecentriq Combination Study
Nov 20 / Zacks.com - Paid Partner Content
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
Nov 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close31.66
Today’s open31.40
Day’s range31.39 - 31.98
Average volume (3 months)1,418,612
Market cap$175.6B
Dividend yield3.25%
Data as of 4:00pm ET, 11/22/2017

Growth & Valuation

Earnings growth (last year)+5.44%
Earnings growth (this year)--
Earnings growth (next 5 years)+6.29%
Revenue growth (last year)+2.58%
P/E ratio19.3


No competitors data available.


Last reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$51.3B
Annual profit (last year)$9.7B
Net profit margin18.93%


Health Technology
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Severin Schwan
Chief Financial &
Information Technology Officer
Alan Hippe
Corporate headquarters
Basel, Basel-stadt (basle Town)